Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-Methoxyestradiol in Plateau Phase or Relapsed Multiple Myeloma
NCT00592579Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2001
- Primary completion
- Sep 2008
- Countries
- 1
- Sponsor
- CASI Pharmaceuticals, Inc.
- Modality
- Small Molecules
- Drugs
- Panzem
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 2, open-label, single-arm trial of Panzem in multiple myeloma (MM), sponsored by CASI Pharmaceuticals, Inc. Primary endpoint: Objective Tumor Response. Started Mar 2001; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Experimental Arm
Open label, oral administration of 2ME2
03
Who it enrols
Adult patients with plateau phase or relapsed multiple myeloma who have received prior chemotherapy, have adequate organ function, and no active infection or recent major surgery.
04
Endpoints
Primary
Objective Tumor Response
Secondary
Safety and Tolerability
Minimum 2ME2 Levels
Beyond the preview
Go deeper on NCT00592579.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592579.